Dr. Jason Westin
Claim this profileM D Anderson Cancer Center
Studies Lymphoma
Studies B-Cell Lymphoma
11 reported clinical trials
21 drugs studied
Area of expertise
1Lymphoma
CD20 positive
CD19 positive
MYC positive
2B-Cell Lymphoma
CD20 positive
CD19 positive
MYC positive
Affiliated Hospitals
Clinical Trials Jason Westin is currently running
Combination Therapy
for B-Cell Lymphoma
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.
Recruiting1 award Phase 2
Cema-cel
for B-Cell Lymphoma
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic CD19 CAR T product, as compared to standard of care observation. The study is conducted in 2 consecutive parts that will be enrolled continuously. In Part A of the study, participants with MRD are randomized to one of two treatment arms or an observation arm. Treatment includes cema-cel following a lymphodepletion regimen of fludarabine and cyclophosphamide administered with or without the anti-CD52 monoclonal antibody, ALLO-647. Part A will culminate with the selection of the lymphodepletion regimen to advance to Part B. Part B will evaluate the selected lymphodepletion regimen followed by cema-cel as compared with observation.
Recruiting1 award Phase 25 criteria
More about Jason Westin
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Jason Westin has experience with
- Lenalidomide
- Tafasitamab
- Ibrutinib
- Molecular Functional Portrait
- Mosunetuzumab
- Polatuzumab Vedotin
Breakdown of trials Jason Westin has run
Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jason Westin specialize in?
Jason Westin focuses on Lymphoma and B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD20 positive patients, or patients who are CD19 positive.
Is Jason Westin currently recruiting for clinical trials?
Yes, Jason Westin is currently recruiting for 4 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Jason Westin has studied deeply?
Yes, Jason Westin has studied treatments such as Lenalidomide, Tafasitamab, Ibrutinib.
What is the best way to schedule an appointment with Jason Westin?
Apply for one of the trials that Jason Westin is conducting.
What is the office address of Jason Westin?
The office of Jason Westin is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.